LSI Europe ’26: What $4.24 Billion in MedTech Exits Means for Your US Market-Access Strategy

A data briefing for MedTech and medical device leaders on this year’s deal data, the agenda, and what it means for your next raise, exit or US launch.

LSI Europe ’26 takes place September 28 to October 1, 2026, in Barcelona. Medtech deal data tells a clear story. European and Israeli MedTech companies are producing real exit value, but 95.6% of it is going to acquirers headquartered outside Europe.

Strategic GPO Consultants authored this briefing to help you understand this deal data and act on it. Our angle is a specific one: US Group Purchasing Organization (GPO) contracting and market access. In our experience, it’s one of the things that separates the medtech companies that turn a strong product into a strong exit from the ones that don’t.

In This Article

1. Conference Snapshot: Dates, Venue, Scale
2. Who’s in the Room: Investors and Strategic Acquirers
3. Agenda at a Glance: What to Prioritize Each Day
4. The Deal Data: What $4.24 Billion in Exits Reveals
5. The Financing Picture: Fewer, Larger Rounds
6. Public and State Capital: The EIC and EIB
7. Who’s Presenting in Barcelona This Year
8. The Open Question: Where Are Europe’s Own Strategics?
9. Where GPOs Fit into the LSI Europe Conversation
10. What Strategic GPO Consultants Offers, and How It Helps LSI Presenting Companies
11. The Investor’s Perspective: GPO Contracts as a De-Risking Signal
12. What This Means for Your Commercialization Strategy
13. Frequently Asked Questions

1. Conference Snapshot: Dates, Venue, Scale

LSI Europe ’26 takes place September 28 to October 1, 2026 at the Grand Hyatt Barcelona. The welcome reception is scheduled on September 28th, and programming runs Tuesday, September 29 through Thursday, October 1. This is the summit’s fifth year, and it has become a fixture on the global MedTech calendar, built around keynotes, structured investor-founder partnering meetings and nonstop startup pitches.

• About 1,000 executives attending
• 228 presenting companies, 146 of them European or Israeli
• About 300 investors and strategic acquirers, which works out to more than one for every presenting company

2. Who’s in the Room: Investors and Strategic Acquirers

Confirmed investors include several of the firms most active in European MedTech dealmaking:

• Sofinnova Partners: the most active private investor in European MedTech by deal count (Antoine Papiernik, Managing Partner & Chairman; Anne Osdoit, Partner)
• Asabys Partners: Josep Ll Sanfeliu, Managing Partner
• Gilde Healthcare, Andera Partners and Nina Capital, among other confirmed venture investors
• The European Innovation Council (EIC) and EIC Fund: in more European MedTech rounds than any single private investor since 2022
• The European Investment Bank (EIB): the region’s most active venture-debt source for clinical-stage MedTech

Confirmed strategic acquirers include leadership from Stryker, Edwards Lifesciences, Conmed, Boston Scientific, Medtronic, Philips, Johnson & Johnson, Abbott, Becton Dickinson, Hologic, Intuitive and W. L. Gore & Associates. Investor panelists include Murielle Thinard McLane (President and Managing Partner, Intuitive Ventures), Antoine Papiernik (Chairman & Managing Partner, Sofinnova Partners), Gautam Kainth (Managing Partner , TCP Health Ventures) and Chris Eso (Senior Vice President, Global Head of Corporate and Business Development, M&A and Ventures, Medtronic).

3. Agenda at a Glance: What to Prioritize Each Day

A guide to the prioritized sessions follows:

Day 1 (Tue, Sept 29): Deal-making and market access

• Keynotes from Bernard Zovighian (Chief Executive Officer: Edwards Lifesciences), Kevin Lobo (Chair & CEO: Stryker) and Matthew Abdel (Chair, Surgical and Procedural Practice; Mayo Clinic)
• The Global Medtech CEO and Investor Roundtable with Antoine Papiernik, Kevin Lobo, Bernard Zovighian and Pat Beyer (Chief Executive Officer; Conmed)
• “Where Medtronic’s 2026 M&A Train Is Heading,” a Q&A with Chris Eso (Senior Vice President, Global Head of Corporate and Business Development, M&A and Ventures: Medtronic)
• Breakouts on US reimbursement strategy, strategic M&A diligence and what the first year of commercialization really looks like

Day 2 (Wed, Sept 30): Exits, investors and AI

• A keynote from Olympic gold medalist Joe Jacobi on high-performance leadership
• “Vessix, SoniVie, and Axonics: Anatomy of Successful Collaborations and Exits”
• “The Transatlantic Gauntlet: How European Startups Can Win in the US Market”
• A fireside chat with Oern Stuge (Investment Committe member; Intuitive Ventures) on dealmaking lessons, plus sessions on raising capital, IP readiness and valuation risk
• A dedicated AI-in-cardiovascular track (ICI @ LSI) in the Loft Room

Day 3 (Thu, Oct 1): Scaling, valuation and the US

• Fireside chat: UNC Health Ventures on its next phase
• “Marks and Markets: Valuation Benchmarks Across the Medtech Capital Stack”
• “Regulatory Clearance in the US and EU: What Startups Need to Know”
• “Cracking the U.S. Market: The Reimbursement Rules Every Medtech Company Needs to Know,” a good bookend for any European company planning its US entry
• A closing session led by Scott Pantel, Founder & CEO of LSI

4. The Deal Data: What $4.24 Billion in Exits Reveals

On August 25, 2025, Terumo agreed to acquire OrganOx, an Oxford spinout that makes liver perfusion technology, for $1.5 billion. It’s the largest European MedTech exit on record, and the buyer was headquartered in Tokyo. That’s the pattern, not the exception. It’s also worth noticing that OrganOx wasn’t a pre-revenue story: its liver perfusion had been FDA-approved since 2021 and on the US market since 2022.

Compass AI, LSI’s data platform, has logged 13 disclosed-value European MedTech acquisitions since January 2025, totaling $4.24 billion. Another six closed without disclosed terms. Of that $4.24 billion:

• 6% went to acquirers headquartered outside Europe
• The only nine-figure deal that stayed in Europe was bioMérieux’s acquisition of Norway’s SpinChip
• Two small deals were European companies buying each other: Affluent Medical’s roll-up of Caranx Medical and Artedrone, and Finland’s Combinostics absorbing Sweden’s SyntheticMR (€4.3M)

Israel stands out on the exit side. Five of the 13 disclosed deals, and 49% of all disclosed exit value, came from Israeli companies: CathWorks, SoniVie, Vectorious, BioProtect and Endospan. Israel is also sending 14 companies to LSI Europe ’26, out of 228 presenting.

5. The Financing Picture: Fewer, Larger Rounds

The median disclosed European MedTech venture round has more than tripled over five years. Total dollars deployed in 2025 roughly matched 2021, but they went to far fewer companies. Capital hasn’t left European MedTech. It has stopped spreading itself thin.

In the last 12 months, Europe produced five rounds of $100M or more: Oura ($908M, Finland), Neko Health ($700M, Sweden), Aidoc ($150M, Israel), Distalmotion ($150M, Switzerland) and CeQur ($100M, Switzerland). There were also strong raises from ViCentra ($85M) and Neurent Medical ($74M).

Europe versus the US, in one line: Europe is the better environment for early-stage runway, with non-dilutive funding and government support. The US offers deeper growth capital, more late-stage investors, and more strategics and IPO routes.

6. Public and State Capital: The EIC and EIB

Public and state-backed investors are now a structural part of European MedTech financing. Since 2022, 24% of European MedTech venture rounds have included one, rising to 33% at Series B. The EIC Fund and EIB are among the most consistently active sources of growth-stage capital, and that’s exactly when serious market-access planning should already be underway.

7. Who’s Presenting in Barcelona This Year

Of the 228 presenting innovators, 146 are European or Israeli. They cluster in cardiovascular (CathWorks, SoniVie, Vectorious, Endospan) and in imaging and diagnostics, where deals are moving fastest, many of them AI-driven (Gleamer to RadNet, icometrix to GE HealthCare, LEX Diagnostics to QuidelOrtho).

• 84 European companies are seeking a combined $1.56B, with a median ask of $12M
• 67% of European and Israeli presenters are still pre-revenue
• 23 companies are asking for $25M or more, led by Nyxoah ($100M), Arga Medtech ($75M), and SamanTree Medical, Newronika and CorWave ($60M each)

8. The Open Question: Where Are Europe’s Own Strategics?

Medtronic, Boston Scientific, Edwards, Olympus, Terumo, RadNet, QuidelOrtho, Artivion, GE HealthCare and J&J have all bought European MedTech innovation in the past 20 months. Europe’s own large caps have mostly looked elsewhere. Philips bought Massachusetts-based SpectraWAVE, and Coloplast bought Minnesota-based Uromedica. Others have made smaller moves, like Getinge’s purchase of UK distributor Pennamed.

Fewer bidders from home means less competition for European companies. We’d argue that costs founders’ real money on exit multiples, though nobody can say exactly how much.

There’s also a regulatory tailwind worth watching. On December 16, 2025, the European Commission proposed a targeted revision of the MDR and IVDR aimed at cutting administrative burden and speeding up certification. It still has to clear the European Parliament and the Council, so the details may change. If it lands close to its current form, it should reduce the time and capital needed to get a device to market in Europe, which helps every European exit.

9. Where GPOs Fit into the LSI Europe Conversation

US Group Purchasing Organizations, including Vizient, Premier and HealthTrust are not among LSI Europe’s confirmed participants alongside investors, strategics, and founders. But they are influential, because they impact almost every outcome this briefing covers, especially medtech commercialization, adoption, and impactful scaling.

• Exits (Section 4): When a strategic acquirer performs due diligence, one question is how quickly the medtech company can commercialize. As healthcare GPOs control approximately 90% of all hospital spend, a medtech start-up without a GPO contract will struggle to scale. Medtech start-ups without GPO contracts are essentially locked out of the market, and experience delayed adoption, and reduced visibility.
• Financing (Section 5): Investors writing today’s larger, more concentrated rounds are looking at US commercial readiness earlier, often before the company has a single US hospital contract.
• Market entry (Section 3, Day 3): The reimbursement and regulatory sessions that close the agenda address hospital reimbursement and achieving FDA clearance. GPO access is the other half of a US launch. FDA clearance allows you to sell, reimbursement helps the hospital get paid, and a GPO contract is ultimately how the hospital buys and how a medtech company is able to effectively commercialize.

GPO contracting is the commercial infrastructure between a strong LSI pitch and a strong US outcome. This is where Strategic GPO Consultants, an internationally recognized GPO Advisory Firm, has the industry expertise to guide medtech companies, both start-up and established.

10. What Strategic GPO Consultants Offers, and How It Helps LSI Presenting Companies

If you’re a European or Israeli company entering the US, GPO strategy is critical for commercialization. It is an integral part of market adoption, commercialization, and scaling. GPO contract categories, Value Analysis Committee (VAC) processes, tiered pricing, and the stakeholder relationships that decide which medtech products even get evaluated are all specific to the US market, and they require the knowledge and experience of a US based GPO Consultant, due to the complexity of the GPO and healthcare contracting landscape. Strategic GPO Consultants closes that gap for companies presenting at LSI Europe ’26.

What we do

• GPO contracting strategy: building an effective corporate GPO contracting strategy, including identification of which national and regional GPOs to target first, and in what order
• Value Analysis Committee (VAC) positioning: preparing the clinical and economic case and value proposition the VAC needs to approve a new product
• National account planning: building the GPO, IDN, and large hospital system relationships that turn a signed contract into actual utilization
• Contract structuring: negotiating tiered pricing and floor-price protection so a contract does not erode your margin over time

How this connects to LSI Europe ’26

• If you’re presenting this year and you are at pre-revenue stage or early stage in the US, we help you build the GPO roadmap that investors and acquirers will ask about in follow-up meetings.
• If you’re already fundraising or in acquisition talks, we assess your GPO readiness against the three questions in Section 11 (diversification, utilization and price protection) before those conversations happen, not after.
• If you’re further out, we help sequence your US entry so GPO contracting work begins early enough to be a strength at your next raise or exit, rather than a gap that diligence finds late.

The best time to bring in this kind of expertise is before you’re fundraising or fielding acquisition interest.

11. The Investor’s Perspective: GPO Contracts as a De-Risking Signal

Investors and acquirers want to know whether your US commercial story will hold up at scale, and your GPO position is one of the clearest windows into that. A company that looks ready for a big exit usually has more than a good product. It has a contracting position that’s hard for competitors to copy. When we look at that position, we ask three questions:

• Diversification: Is your company contracted with more than one national GPO, or is a single contract carrying everything?
• Utilization: Of the hospitals that have access to the contract, what percentage are actually ordering?
• Price protection: Does the contract include floor-price protections to keep you out of a race to the bottom?

This is the checklist we use, in that order, when we advise clients ahead of a raise or acquisition talks. It’s our own framework rather than an industry standard, but the questions behind it are ones a careful diligence team is likely to ask.

A GPO contract doesn’t guarantee sales, and utilization is the real test. Still, going without one can make a raise or a sale harder, because selling hospital by hospital without a contract is slow and expensive.

12. What This Means for Your Commercialization Strategy

Put the exit data, the financing pattern and the public-capital backstop side by side, and one thing stands out. Market access and commercial readiness are now part of how companies get valued, not something to sort out after the deal. Acquirers want to know how quickly your product can move through GPO and IDN channels inside a bigger organization. Investors are asking the same question earlier, at financing.

If you’re presenting in Barcelona, it’s worth working on that readiness before the meetings start.  Strategic GPO Consultants is the most experienced and credentialed GPO Consulting Firm in the industry.. If you’re still building toward your first major GPO contract or national account win, treat LSI Europe ’26 as a market-access research trip as much as a fundraising event. The companies in the best shape in Barcelona will be the ones that built commercial readiness in from day one.

Want a second opinion on your GPO position before you attend the meeting? Get in touch with Strategic GPO Consultants.

13. Frequently Asked Questions

When and where are LSI Europe ’26?

September 28 to October 1, 2026, at the Grand Hyatt Barcelona. The 28th is the welcome reception, and programming runs September 29 through October 1.

How many people attend LSI Europe ’26?

Roughly 1,000 executives, 228 presenting companies, and about 300 investors and strategic acquirers.

Why do 95.6% of disclosed European MedTech exits go to non-European acquirers?

Our read is that Europe’s large strategics have mostly done smaller deals or bought outside Europe. That leaves US- and Asia-headquartered companies as the main buyers at scale.

Why does Israel account for 49% of disclosed exit value?

Part of it is arithmetic: Israeli companies made up five of the 13 deals, and those five were larger than average. Our read on the rest is that Israeli MedTech companies often build their clinical, regulatory and commercial plans around a sale to a global strategic from an early stage.

Do US Group Purchasing Organizations (GPOs) attend LSI Europe?

GPOs aren’t typically among LSI Europe’s confirmed attendees. Participants are mostly venture, private equity, strategics, corporate development, and medtech founders. But GPO contracting status is one of the clearer signals of a company’s US commercial readiness (see Section 9).

Why do investors care about GPO contracts?

Because it indicates whether a medtech company can scale commercially at reasonable cost, which feeds into exit valuation and follow-on financing.

How can a company presenting at LSI Europe ’26 work with Strategic GPO Consultants?

You can request a GPO-readiness assessment before, during or after the conference. We benchmark your current contracting position against the three questions in Section 11 (diversification, utilization and price protection) and build a sequencing plan for your US entry.

When should a European MedTech company bring in a US GPO consulting partner?

Early, ideally before fundraising or acquisition discussions begin. GPO strategy takes years to build, and investors look at it well ahead of an exit.